TG-1801: Clinical Trials

2 trials of TG-1801, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Terminated 1

Follow TG-1801: new trials by email Literature Review of TG-1801 trials Research Report on TG-1801

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
TG-1801, Ublituximab - CLL, SLL
Phase 1TerminatedTG Therapeutics, Inc.212021-04-282024-07-31
Study of TG-1801 in Subjects With B-Cell Lymphoma
TG-1801, Ublituximab - B-Cell Lymphoma
Phase 1CompletedTG Therapeutics, Inc.502019-03-052024-04-08

Conditions studied

Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Recurrence (1)

Sponsors

TG Therapeutics, Inc. (2)

Countries

Australia (1)  ·  United States (1)

Results publications

PMID 35538512